Zai Lab

Yahoo Finance • 3 months ago

Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

Late-breaking oral presentation will discuss the potential of ZL-1503 as a novel treatment for moderate-to-severe atopic dermatitis and other diseases involving the IL-13 and IL-31 pathways ZL-1503 is part of Zai Lab’s internally discover... Full story

Yahoo Finance • 6 months ago

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

SHANGHAI & CAMBRIDGE, Mass., June 11, 2024--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Auto... Full story

Yahoo Finance • 10 months ago

Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results

Total Revenue: Zai Lab Ltd (NASDAQ:ZLAB) reported a 25% increase in product revenue, reaching $266.7 million for the full year of 2023. Net Loss Improvement: Net loss decreased to $334.6 million in 2023 from $443.3 million in the previous... Full story

Yahoo Finance • last year

Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List

SHANGHAI & CAMBRIDGE, Mass., December 13, 2023--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administrati... Full story

Yahoo Finance • last year

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

Zai Lab Limited Total product revenue of $69.2 million for the third quarter of 2023, representing 22% y-o-y growth; 27% y-o-y growth at constant exchange rate (CER) VYVGART® (efgartigimod alfa injection) achieved $4.9 million sales sinc... Full story

Yahoo Finance • last year

13 Stocks to Buy with Exponential Growth

In this article, we will take a look at the 13 stocks to buy with exponential growth. To see more such companies, go directly to 5 Stocks to Buy with Exponential Growth. Optimism was prevailing in the US stock market on October 11 as inve... Full story

Yahoo Finance • last year

Why Shares of Zai Lab Limited Were Jumping on Tuesday

Shares of Zai Lab (NASDAQ: ZLAB) were up more than 10% as of 11 a.m. on Tuesday. The Chinese biotech stock rose after the company announced positive phase 3 trial data regarding Tivdak as a front-line therapy to treat metastatic cervical c... Full story

Yahoo Finance • last year

11 Most Profitable Biotech Stocks Today

In this piece, we will take a look at the 11 most profitable biotechnology stocks to buy today. If you want to skip our introduction to the biotechnology industry and want to take a look at the top five stocks in this list, then head on ov... Full story

Yahoo Finance • last year

Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm

NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Xponential Fitness, Inc. (NYSE: XPOF), Franchise Group, Inc. (NASDAQ:... Full story

Yahoo Finance • last year

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation – ZLAB

NEW YORK, July 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from all... Full story

Yahoo Finance • last year

Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Hayward and Encourages Investors to Contact the Firm

NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Xponential Fitness, Inc. (NYSE: XPOF), Franchise Group, Inc. (NASDAQ:... Full story

Yahoo Finance • last year

全國出庭律所 ROSEN 鼓勵 Zai Lab Limited 投資者查詢 ZLAB 證券集體訴訟調查狀況

紐約, June 26, 2023 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 宣布代表 Zai Lab Limited (NASDAQ: ZLAB) 的股東進行潛在證券索賠調查，原因是有指控稱 Zai Lab 可能向投資大眾發布了嚴重誤導性的商務資訊。 影響：倘若您曾購買 Zai Lab 證券，您可能有權透過勝訴收費安排獲得賠償，而無需支付任何自付費用或訟費。Rosen Law Firm 正在準備發起一項集體... Full story

Yahoo Finance • last year

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation – ZLAB

WHY: NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from alle... Full story

Yahoo Finance • 2 years ago

ZLAB INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation – ZLAB

NEW YORK, June 14, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from alle... Full story

Yahoo Finance • 2 years ago

Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates

Total product revenue of $62.8 million for the first quarter of 2023, representing a 36% increase y-o-y; ZEJULA® achieved 44% y-o-y growth Expansion of Zai Lab’s lung cancer franchise and global oncology pipeline with a next generation ant... Full story

Yahoo Finance • 2 years ago

Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting

Zai Lab Limited New translational and clinical biomarker data from Zai Lab’s global oncology program ZL-1211 will be featured in a poster presentation (Abstract presentation number: 4531) SHANGHAI and CAMBRIDGE, Mass., April 11, 2023 (GL... Full story

Yahoo Finance • 2 years ago

1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off

There's a good chance that Zai Lab's (NASDAQ: ZLAB) stock will make a journey into the stratosphere in the next few years, and that means growth-hungry investors should consider loading up on its shares, and soon. Whereas other mid-cap bio... Full story

Yahoo Finance • 2 years ago

Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA

Zai Lab Limited SHANGHAI and CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has accepted the New Drug Applic... Full story

Yahoo Finance • 2 years ago

Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Zai Lab Limited The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival The full LUNAR data will be presented at a future medical congress SHANGHAI an... Full story

Yahoo Finance • 2 years ago

Zai Lab Announces Participation in January Investor Conferences

Zai Lab Limited SHANGHAI, China and CAMBRIDGE, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that se... Full story